Immunome, Inc. (NASDAQ:IMNM) Insider Purchases $149,831.40 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider purchased 15,805 shares of the stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now directly owns 15,805 shares of the company’s stock, valued at $149,831.40. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Immunome Stock Up 16.8 %

Shares of Immunome stock opened at $13.47 on Thursday. The business has a 50 day moving average of $12.41 and a 200 day moving average of $13.52. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96. The company has a market cap of $840.80 million, a PE ratio of -1.65 and a beta of 1.82.

Wall Street Analyst Weigh In

Several research analysts have recently commented on IMNM shares. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Stephens began coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Piper Sandler dropped their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $28.83.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC bought a new stake in shares of Immunome during the 2nd quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Immunome in the 2nd quarter worth approximately $97,000. Arizona State Retirement System increased its position in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after buying an additional 918 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in Immunome in the 2nd quarter worth about $206,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.